Healthcare provider profile · identity verified

Richard H Bernhardt, MD

Internal Medicine · MOORESVILLE, IN · NPI 1487850988

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	375	105
Levothyroxine Sodium	Levothyroxine Sodium	292	61
Lisinopril	Lisinopril	285	78
Omeprazole	Omeprazole	248	59
Amlodipine Besylate	Amlodipine Besylate	222	59
Gabapentin	Gabapentin	172	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	165	20
Metformin Hcl	Metformin Hcl	144	38
Losartan Potassium	Losartan Potassium	135	35
Trazodone Hcl	Trazodone Hcl	130	30
Hydrochlorothiazide	Hydrochlorothiazide	128	35
Metoprolol Succinate	Metoprolol Succinate	126	25
Albuterol Sulfate Hfa	Albuterol Sulfate	110	31
Pantoprazole Sodium	Pantoprazole Sodium	107	30
Escitalopram Oxalate	Escitalopram Oxalate	103	28
Fluticasone Propionate	Fluticasone Propionate	86	33
Tamsulosin Hcl	Tamsulosin Hcl	81	18
Sertraline Hcl	Sertraline Hcl	76	20
Meloxicam	Meloxicam	75	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	74	22
Ropinirole Hcl	Ropinirole Hcl	72	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	70	17
Mounjaro	Tirzepatide	68	11
Simvastatin	Simvastatin	67	17
Duloxetine Hcl	Duloxetine Hcl	66	14
Jardiance	Empagliflozin	63	15
Ozempic	Semaglutide	63	17
Rosuvastatin Calcium	Rosuvastatin Calcium	63	22
Pregabalin	Pregabalin	62	12
Spiriva Handihaler	Tiotropium Bromide	61	suppressed
Furosemide	Furosemide	54	15
Tramadol Hcl	Tramadol Hcl	53	suppressed
Alprazolam	Alprazolam	52	suppressed
Montelukast Sodium	Montelukast Sodium	52	11
Amitriptyline Hcl	Amitriptyline Hcl	49	suppressed
Eliquis	Apixaban	49	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	49	11
Clonazepam	Clonazepam	43	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	43	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	43	suppressed
Cephalexin	Cephalexin	42	26
Ipratropium Bromide	Ipratropium Bromide	41	28
Citalopram Hbr	Citalopram Hydrobromide	38	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	34	suppressed
Prednisone	Prednisone	34	19
Allopurinol	Allopurinol	33	suppressed
Baclofen	Baclofen	33	suppressed
Lorazepam	Lorazepam	32	suppressed
Paroxetine Hcl	Paroxetine Hcl	31	suppressed
Diazepam	Diazepam	30	suppressed
Ondansetron Hcl	Ondansetron Hcl	30	suppressed
Bupropion Xl	Bupropion Hcl	29	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Glipizide Er	Glipizide	26	suppressed
Metformin Hcl Er	Metformin Hcl	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	11
Bupropion Hcl	Bupropion Hcl	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Carvedilol	Carvedilol	22	suppressed
Fluconazole	Fluconazole	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Temazepam	Temazepam	22	suppressed
Atenolol	Atenolol	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	20	suppressed
Loperamide	Loperamide Hcl	20	suppressed
Estradiol	Estradiol	19	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	15
Finasteride	Finasteride	16	suppressed
Naproxen	Naproxen	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Divalproex Sodium	Divalproex Sodium	15	suppressed
Potassium Chloride	Potassium Chloride	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Varenicline Tartrate	Varenicline Tartrate	15	suppressed
Hydrocortisone	Hydrocortisone	14	14
Methocarbamol	Methocarbamol	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Wegovy	Semaglutide	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Invokana	Canagliflozin	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Paliperidone Er	Paliperidone	13	suppressed
Ramipril	Ramipril	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Tresiba Flextouch U-200	Insulin Degludec	13	suppressed
Valsartan	Valsartan	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Fentanyl	Fentanyl	12	suppressed
Topiramate	Topiramate	12	suppressed
Torsemide	Torsemide	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Digoxin	Digoxin	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Famotidine	Famotidine	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error